EUVIMEDScopri EUVIMED
Crossref

Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment

Jingyi Bi, Xuelin Dou, Ruqi Liang, Lei Wen, Yang Liu, Xiaoguang Lei, Liru Wang, Huixia Guo, Xiaojun Huang, Mingdi Wang, Jin Lu

Acta Haematologica · 2025

DOI: 10.1159/000545709 ↗

At a glance

Journal article in Acta Haematologica, 2025. Written by Jingyi Bi and 10 co-authors. Institution: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, C…. Major MEDLINE topics: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Hydroxamic Acids. Cited 1 times so far (Crossref).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

We conducted a single-arm, open-label dose-exploration study to evaluate the safety and efficacy of the histone deacetylase inhibitor tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone (C-PDD) in treating relapsed and refractory multiple myeloma (RRMM) patients.

Methods

Eighteen patients were enrolled from August 2020 to May 2021, receiving 21-day cycles of C-PDD.

Results

Eighteen cases were analyzed, with a median prior treatment line of 2 (range: 1-4). The median number of completed treatment cycles was 4 (range: 1-8). The overall response rate was 57%, including 14% complete response, 14% very good partial response, and 29% partial response. Both bortezomib-sensitive and refractory groups had a response rate of 57%. The response rate was 100% in patients with extramedullary extraosseous involvement. The median follow-up was 42 months (range: 3-44), with median progression-free survival of 7 months and median overall survival of 24.5 months. Grade 3-4 hematologic adverse events included thrombocytopenia (50%), neutropenia (33%), and anemia (33%). Non-hematologic adverse events were mostly grade 1-2, with one case of grade 3 peripheral sensory neuropathy.

Conclusion

The C-PDD regimen showed efficacy in RRMM, including bortezomib-refractory disease and EME patients. The optimal dose and combination need to be explored in the future.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHydroxamic AcidsHumansBortezomibMaleFemaleDoxorubicinDexamethasoneMiddle AgedAgedAdultAged, 80 and overTreatment OutcomePolyethylene Glycols

Author keywords

BortezomibRelapsed and/or refractory multiple myelomaTucidinostat

Substances

BortezomibDoxorubicinDexamethasoneliposomal doxorubicinHydroxamic AcidsPolyethylene Glycols

Authors and institutions

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Peking University College of Chemitry and Molecular Engineering, Beijing, China.
  • Fuxing Hospital, Capital Medical University, Beijing, China.
  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China, 5290675@qq.com.
  • Hematology Department, Peking University Shougang Hospital, Beijing, China, 5290675@qq.com.
  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China, lujin@pku.edu.cn.

Cite

APA

Bi, J., Dou, X., Liang, R., Wen, L., Liu, Y., Lei, X., Wang, L., Guo, H., Huang, X., Wang, M., & Lu, J. (2025). Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment. Acta Haematologica. https://doi.org/10.1159/000545709

Vancouver

Bi J, Dou X, Liang R, Wen L, Liu Y, Lei X, et al. Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment. Acta Haematologica. 2025. doi:10.1159/000545709

BibTeX
@article{Bi2025,
  author = {Bi, Jingyi and Dou, Xuelin and Liang, Ruqi and Wen, Lei and Liu, Yang and Lei, Xiaoguang and Wang, Liru and Guo, Huixia and Huang, Xiaojun and Wang, Mingdi and Lu, Jin},
  title = {Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment},
  journal = {Acta Haematologica},
  year = {2025},
  doi = {10.1159/000545709}
}
Start for free →